Biological age isn’t just a number.
What’s happening: Infinite Epigenetics, parent company of TruDiagnostic, acquired consumer longevity company Tally Health.
Constituting the “largest asset purchase in epigenetic testing,” Tally CEO Melanie Goldey will stay on to lead operations as a standalone brand.
All-in-one. A full-stack platform, Infinite Epigenetics uses DNA methylation data to power biological age tests via TruDiagnostic.
Co-founded in 2023 by Harvard professor Dr. David Sinclair, Tally went DTC, pairing epigenetic tests with supplements and lifestyle recommendations — and striking partnerships with Cenegenics and Pvolve to reach biohacking and general wellness consumers.
Combining clinical infrastructure with consumer distribution, the combined company now controls one of the world’s largest private adult DNA methylation datasets. Connecting testing to intervention, its vertical integration tightens the feedback loop between data, recommendations, and outcomes.
Age of aging. Like step counts and sleep scores, biological age has become a mainstream metric consumers can optimize.
Decoding and slowing aging, Elysium Health, MyDNAge, GlycanAge, and iAge are scaling at-home tests and interventions as the epigenetic diagnostics market nears $20B.
Punchline: Positioning biological age as the future of preventative care, Infinite Epigenetics is building a full-stack model, connecting data and action.
